Trial Profile
A comparative,prospective, nationwide study of Inflectra (biosimilar monoclonal antibody) and Remicade for inducing and maintaining remission in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) in Hungarian patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Hospira
- 01 Nov 2017 Final results from a prospective nationwide inflammatory bowel disease cohort presented at the 25th United European Gastroenterology Week
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 19 Oct 2016 Results (n= 291) presented at the 24th United European Gastroenterology Week